These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33432013)

  • 1. Transformer neural network for protein-specific de novo drug generation as a machine translation problem.
    Grechishnikova D
    Sci Rep; 2021 Jan; 11(1):321. PubMed ID: 33432013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FSM-DDTR: End-to-end feedback strategy for multi-objective De Novo drug design using transformers.
    Monteiro NRC; Pereira TO; Machado ACD; Oliveira JL; Abbasi M; Arrais JP
    Comput Biol Med; 2023 Sep; 164():107285. PubMed ID: 37557054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Training recurrent neural networks as generative neural networks for molecular structures: how does it impact drug discovery?
    D'Souza S; Kv P; Balaji S
    Expert Opin Drug Discov; 2022 Oct; 17(10):1071-1079. PubMed ID: 36216812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generative Pre-trained Transformer (GPT) based model with relative attention for de novo drug design.
    Haroon S; C A H; A S J
    Comput Biol Chem; 2023 Oct; 106():107911. PubMed ID: 37450999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DockingGA: enhancing targeted molecule generation using transformer neural network and genetic algorithm with docking simulation.
    Gao C; Bao W; Wang S; Zheng J; Wang L; Ren Y; Jiao L; Wang J; Wang X
    Brief Funct Genomics; 2024 Sep; 23(5):595-606. PubMed ID: 38582610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generative Chemical Transformer: Neural Machine Learning of Molecular Geometric Structures from Chemical Language via Attention.
    Kim H; Na J; Lee WB
    J Chem Inf Model; 2021 Dec; 61(12):5804-5814. PubMed ID: 34855384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo generation of dual-target ligands using adversarial training and reinforcement learning.
    Lu F; Li M; Min X; Li C; Zeng X
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34410338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Transferable Compound Representation across Domains and Tasks for Low Data Drug Discovery.
    Abbasi K; Poso A; Ghasemi J; Amanlou M; Masoudi-Nejad A
    J Chem Inf Model; 2019 Nov; 59(11):4528-4539. PubMed ID: 31661955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The power of deep learning to ligand-based novel drug discovery.
    Baskin II
    Expert Opin Drug Discov; 2020 Jul; 15(7):755-764. PubMed ID: 32228116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in de Novo Drug Design: From Conventional to Machine Learning Methods.
    Mouchlis VD; Afantitis A; Serra A; Fratello M; Papadiamantis AG; Aidinis V; Lynch I; Greco D; Melagraki G
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Target Interaction Prediction: End-to-End Deep Learning Approach.
    Monteiro NRC; Ribeiro B; Arrais JP
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(6):2364-2374. PubMed ID: 32142454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generative machine learning for de novo drug discovery: A systematic review.
    Martinelli DD
    Comput Biol Med; 2022 Jun; 145():105403. PubMed ID: 35339849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generative Recurrent Networks for De Novo Drug Design.
    Gupta A; Müller AT; Huisman BJH; Fuchs JA; Schneider P; Schneider G
    Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29095571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforced Adversarial Neural Computer for de Novo Molecular Design.
    Putin E; Asadulaev A; Ivanenkov Y; Aladinskiy V; Sanchez-Lengeling B; Aspuru-Guzik A; Zhavoronkov A
    J Chem Inf Model; 2018 Jun; 58(6):1194-1204. PubMed ID: 29762023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Integration Using Advances in Machine Learning in Drug Discovery and Molecular Biology.
    Hudson IL
    Methods Mol Biol; 2021; 2190():167-184. PubMed ID: 32804365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
    Polykovskiy D; Zhebrak A; Vetrov D; Ivanenkov Y; Aladinskiy V; Mamoshina P; Bozdaganyan M; Aliper A; Zhavoronkov A; Kadurin A
    Mol Pharm; 2018 Oct; 15(10):4398-4405. PubMed ID: 30180591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Synthesizability of Molecules Proposed by Generative Models.
    Gao W; Coley CW
    J Chem Inf Model; 2020 Dec; 60(12):5714-5723. PubMed ID: 32250616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep generative model for drug design from protein target sequence.
    Chen Y; Wang Z; Wang L; Wang J; Li P; Cao D; Zeng X; Ye X; Sakurai T
    J Cheminform; 2023 Mar; 15(1):38. PubMed ID: 36978179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Drug Design Using Transformer-Based Machine Translation and Reinforcement Learning of an Adaptive Monte Carlo Tree Search.
    Ang D; Rakovski C; Atamian HS
    Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Convolutional Generative Adversarial Network (dcGAN) Models for Screening and Design of Small Molecules Targeting Cannabinoid Receptors.
    Bian Y; Wang J; Jun JJ; Xie XQ
    Mol Pharm; 2019 Nov; 16(11):4451-4460. PubMed ID: 31589460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.